Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Phase 1
20
about 5.5 years
18+
1 site in IL
What this study is about
This trial is testing the safety and feasibility of giving repeated doses of a treatment called NSC-CRAd-S-pk7 to people with newly diagnosed high grade glioma. The main questions are whether this treatment is safe, if it affects tumor response, overall survival, time to progression, and quality of life.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive NSC-CRAd-S-pk7
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Dose-limiting toxicity of repeat NSC-CRAd-S-pk7 dosing
Secondary: Objective response to therapy, Overall survival, Progression-free survival
Oncology